MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announces the presentation of results from a study of LUNESTA® brand eszopiclone that measured the effects on actual next-morning driving ability and other objective assessments of cognitive and psychomotor function. Results from this randomized, double-blind, placebo-controlled, two-way crossover study in patients with primary insomnia will be presented today at the American College of Neuropsychopharmacology annual meeting in Hollywood, Fla. This study is unique in that it was comprised of patients with insomnia who drove automobiles in a controlled environment, in contrast to other driving studies conducted in computer-generated driving simulators.
